Agenus Inc.

3 Forbes Road
Lexington
Massachusetts
02421
United States

Tel: 781-721-3500
Fax: 781-938-6496

Email: info@antigenics.com

Show jobs for this employer

307 articles with Agenus Inc.

  • It was a moderately busy week for clinical trial news, with some important reports coming out about COVID-19 vaccines. Here’s a look.
  • Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced updated timing of the balstilimab BLA filing to meet the FDA feedback to follow all patients for a median of 12 months and responders for a minimum of 6 months

  • Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jennifer Buell, President and COO of Agenus, will participate in a fireside chat hosted by Umer Raffat at the Evercore ISI 3rd Annual HealthCONx Conference on Thursday,

  • Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jennifer Buell, President and COO of Agenus, will participate in a fireside chat at the Jefferies 2020 Virtual London Healthcare Conference on Tuesday, November 17, 2020 from 4:25 PM – 4:55 PM GMT / 11:25 AM –

  • Agenus Inc. announced that Dr. Steven O’Day, Executive Director of the John Wayne Cancer Institute, Dr. Jennifer Buell, President and COO of Agenus, and Dr. Dhan Chand, Scientific Director Head of Drug Discovery at Agenus, will participate in a webcast hosted by Dr. Matt Phipps of William Blair on Monday, November 16, 2020 at 10:00 a.m. ET.

  • Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Steven O’Day, Executive Director of the John Wayne Cancer Institute, Dr. Jennifer Buell, President and COO of Agenus, and Patrick Jordan, COO of AgenTus Therapeutics

  • Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that a milestone payment of $10M from Merck has been triggered with the advancement of an ILT4 antibody, MK-4830, into a Phase 2 clinical trial.

  • It was relatively quiet in terms of COVID-19-related clinical trials, but there was still quite a bit of news for trials involving other indications. Here’s a look.
  • AGEN1181 : New clinical responses and intratumoral Treg depletion AGEN 1777 ( TIGIT ) is Fc enhanced for optimized immune performance & broader benefit AGEN2373 (anti-CD137) : Clinical benefit with no liver toxicity Allogeneic iNKTs : Potent tumor cell killing and tumor microenvironment regulation VISION : Proprietary platform for response prediction and optimal combos Zalifrelimab (anti-CTLA-4) : 1 CR, 2 PRs, and 52% benefit in PD-1 refractory tumors

  • Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
  • Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the appointment of Dr. Steven O’Day, MD, as its Chief Medical Officer.

  • Agenus Inc. (NASDAQ: AGEN),announced the dosing of the first COVID-19 patient with agenT-797, an allogeneic cell therapy, through its subsidiary, AgenTus Therapeutics.

  • Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate and optimize immune response to cancers and infections, today provide

  • Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it will release its third quarter 2020 financial results before the market opens on Thursday, October 29, 2020. Agenus executives will host a conference call and webcast at 8:30 a.m. ET the same day to discuss the result

  • Biopharma and life sciences companies bolster their leadership teams with these Movers & Shakers.
  • Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that seven abstracts were accepted for presentation at the virtual SITC 2020 Annual Meeting from November 9-14, 2020.

  • Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the election of Ms. Susan Hirsch to Agenus' Board of Directors.

  • 160 patient balstilimab (PD-1) monotherapy trial achieves response rates of 14% in all treated patients and 19% in PD-L1 positive patients

  • Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, announced the initiation of the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for balstilimab alone for the treatment of recurrent/metastatic cervical cancer.

  • Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jennifer Buell, President and COO of Agenus, spoke to Jeremy Abbate, Publisher of Scientific American